Internet Archive Scholar

Should renin angiotensin aldosterone system inhibition enablement be a therapeutic target in CKD patients?

Patrick Rossignol, Rajiv Agarwal
2021 Nephrology, Dialysis and Transplantation  

Preserved Fulltext

fulltext thumbnail
Web Archive Capture PDF (104.0 kB)
https://web.archive.org/web/20210308030008/https://watermark.silverchair.com/gfab061.pdf?token=AQECAHi208BE49Ooan9kkhW_Ercy7Dm3ZL_9Cf3qfKAc485ysgAAArEwggKtBgkqhkiG9w0BBwagggKeMIICmgIBADCCApMGCSqGSIb3DQEHATAeBglghkgBZQMEAS4wEQQMyRZbEYh7Ea2mGVU0AgEQgIICZJZGpMBLTLC1h_cXOPxq_m8pXrIF-VqaUOX_ShAGBchgAus95UfS63amb5FLFfMGy6sCuYQM6Z3inRF8CbvuEXPqTCLh2ZE5DfXtxcfTTuPmy50XhkefjCHV-pbp_8wBoTqfjEItdlpXV_6A-PVRR6y6FLBt_jmQNA4CPpxeRfOLszQOTL2nBYX8V8tijCHRAF38eGyB-4Teo_wN9Gahm5mkQnl5EFOIAMx4OwZ2d4Yg-kyHE1XFh-nf6BMIMS_Xgyoote7aX7je6w8hN4pivOowdwPj8Ir8RfOk4596xywnLdXuRsqRM0I38oGCAQQKuwvW9DAm1WABnKQ7tm36Impoe6UHbxzqympeSqVM2XXd8iaNlJIke5UpO7c_hOwGGV36WAlNleeSDXofu8JFcVkr7sRtS_ydW_s-K7rke5tuA6fVRmr9PuLjo4cemm6ZgTbwhVk6t7aP_uDF03SbZzN7e-_0ElyQfYOGT5ErOaBqvBW5UImK8niT-SXCAT9z22OPkED4LTgcmtdfXFJL4Eaip-ogpL4fTlieboO3N5xSy5nFG3nRYfldzoD0vY9VkTS1aALreUk2znmNKPsb6AXTehfTGZgCKYBVdACiYvIeR9UjALnP5Uu7jhFhaDCynF8DBi71cRpEYiMcu40wv-4kfv9sVXTG-QP3isbkRz4txlsekMdern7RqTYjKioCNGPfbWwuMYCJx3H_FZHrt9NYgx0QXJ7Bu0WU-paddPYmcXqbebixD1vUkhbmxHW7sm5uDKP89gjAKcsNBVXu8QpdCbvgGTISZgaOrizqtm8RmybqWg

A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2021; you can also visit the original URL. The file type is application/pdf.

Keywords: cardiorenal syndrome, chronic kidney disease, hyperkalaemia, mineralocorticoid receptor antagonist, renin angiotensin aldosterone system inhibitor Renin angiotensin aldosterone system (RAAS) inhibitor use is of paramount importance in patients with diabetes, hypertension, heart failure and reduced ejection fraction (HFrEF-the latter frequently
doi:10.1093/ndt/gfab061 pmid:33677569 fatcat:emcpojzjx5clfb7nf6fmuhujxi
Citation

Patrick Rossignol, Rajiv Agarwal. "Should renin angiotensin aldosterone system inhibition enablement be a therapeutic target in CKD patients?." Nephrology, Dialysis and Transplantation 36.10 (2021)